Rosalyn Juergens

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer

New England Journal of Medicine · 2017 · 2,096 citations

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

The Lancet Oncology · 2017 · 797 citations